News and Trends 14 Oct 2019 Mogrify Raises €15M Series A to Chase the ‘Holy Grail’ of Cell Therapy Cambridge-based Mogrify has raised €14.5M to develop a technology that could allow scientists to transform any human cell into another cell type without the arduous process of turning them into a stem cell first. The Series A round was led by Ahren Innovation Capital, an investment firm founded by science entrepreneurs from the UK […] October 14, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2019 Update: BioNTech Files for €141M Nasdaq IPO BioNTech’s Nasdaq IPO has raised €141M ($155M), a lower sum than it initially anticipated. The timing of the IPO means it has likely been impacted by adverse market conditions, which are due to factors such as global manufacturing slowdowns and escalations in US and Chinese trade disputes. This same market volatility led several companies such […] October 10, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Oct 2019 UK Company and Merck Team Up to Develop Vaccines Based on the Microbiome Merck will pay the microbiome company 4D Pharma up to €316.5M to develop vaccines based on delivering live bacteria to the gut. The partners will develop vaccines against three undisclosed conditions. As well as an undisclosed upfront fee for each condition, 4D Pharma will be eligible to receive up to €316.5M ($347.5M) in developmental milestones. […] October 8, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2019 ADC Therapeutics Cancels Nasdaq IPO Amidst Market Growth Fears The Swiss biotech ADC Therapeutics has withdrawn its application for a €182M ($200M) Nasdaq IPO, citing adverse market conditions caused by global manufacturing slowdowns. ADC Therapeutics declined to comment on the specific market situation. Its withdrawal is likely due to slumps in European and US stock markets seen earlier this week caused by drops in […] October 4, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2019 RNA Therapies, Immunotherapies and Cancer Tests Showcased in Spain Biotech companies around the world gathered in Barcelona, Spain, to present breakthroughs in cancer diagnostics and treatments such as cell therapies and cancer vaccines. Here’s our take on the most interesting offerings from the European crop. Barcelona is the home of Gaudi and Barcelona Football Club. Over the last few days, it was also the […] October 2, 2019 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2019 Update: Mixed Results for Adocia as Legal Fight with Eli Lilly Comes to a Close Update (30/09/2019): A long legal battle between Adocia and Eli Lilly over a fast-acting insulin treatment development deal has finished with mixed results for Adocia. Eli Lilly has now paid €13M to Adocia, after the US Arbitration Association Panel supported Adocia’s claim last year. The payment consists of a milestone payment of €10.1M plus interest. […] September 30, 2019 - 4 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2019 €20M Series A Launches Cancer Immunotherapy Biotech in Denmark The Danish company STipe Therapeutics has been launched with a €20M Series A to develop immunotherapy drugs that sensitize the innate immune system against cancer. STipe Therapeutics was spun out from Aarhus University, Denmark, last year with a small grant, and has now completed its full launch with this Series A. The round was co-led […] September 30, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2019 Positive Phase III Results for Narcolepsy Drug with Low Cardiovascular Risk The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease. In a 200-patient phase III trial that finished in July, Jazz Pharmaceutical’s experimental drug was able to reduce the number of cataplexy attacks and the […] September 26, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Sep 2019 Danish Smallpox Vaccine Gets FDA Approval to Fight Bioterrorism A vaccine developed by the Danish company Bavarian Nordic has received FDA approval to prevent infections by monkeypox, as well as protect against the threat of a smallpox bioterror attack. This approval makes Bavarian Nordic’s vaccine the only approved vaccine in the world for preventing monkeypox, a rare viral infection that is similar to smallpox […] September 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Sep 2019 German Biotech Will Develop Carbohydrate-Targeting Cancer Treatments The German startup Tacalyx has raised €7M in a seed round to fund the preclinical development of first-in-class carbohydrate-targeting antibody drugs for the treatment of cancer. The round was co-led by the Germany-based Boehringer Ingelheim Venture Fund and the French VC firm Kurma Partners. Tacalyx will use the money to generate a lead candidate antibody […] September 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 24 Sep 2019 Rare Metal Could Turbocharge Cancer Light Therapies A team of European and Chinese researchers has developed a light-activated cancer therapy containing the rare metal iridium that could potentially activate the immune system against cancer. In a study published in Nature Chemistry, the drug killed multiple types of cancer cells in a dish when activated by red light. The study also revealed that […] September 24, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 24 Sep 2019 Lab-Grown Skin as Good as Skin Grafts for Burns at Phase III Mallinckrodt’s treatment made of artificial skin tissue called Stratagraft closed over 80% of second-degree burn wounds in a phase III trial, matching the effectiveness of skin grafts. Mallinckrodt recruited 71 patients with second-degree burns who were eligible for skin grafts into the trial. Each patient received the artificial skin graft on some areas of burned […] September 24, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email